Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
about
Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitisTargeting Non-classical Myelin Epitopes to Treat Experimental Autoimmune EncephalomyelitisA risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.Immunotherapy Applied to Neuropsychiatric Disorders: a New Perspective of Treatment.Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study.Cytomegalovirus appendicitis after hematopoietic stem cell transplantation.Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.
P2860
Q33800615-DF2FB225-85ED-457A-9C48-C589FAF0F5E5Q37379542-B06F55FF-C476-4BBA-BFF9-448F7658D33DQ38268951-2C3C3492-4DB1-49CF-A71B-E75FB756A0C4Q38508754-6B2E9BF2-355F-4E56-A606-F14897601373Q39016381-55C34FFB-D891-4E19-9E8C-5DE375674D3CQ40122855-BD7FC351-A73E-430E-8168-05F3AD28AFC9Q41995022-11EE8C14-0707-4E20-A2BA-6A84D6D0A02C
P2860
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@ast
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@en
type
label
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@ast
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@en
prefLabel
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@ast
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@en
P2860
P356
P1433
P1476
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
@en
P2093
Carrie M Hersh
Jeffrey A Cohen
P2860
P304
P356
10.2217/IMT.14.7
P577
2014-01-01T00:00:00Z